Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models
about
Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advancesRoles of FGFs As Paracrine or Endocrine Signals in Liver Development, Health, and DiseaseNovel hepatocellular carcinoma molecules with prognostic and therapeutic potentialsFibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders.Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesRegulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR systemThe Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes.Thrombocytosis and hepatocellular carcinoma.Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro.Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters.Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis.Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma.Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma.The Fibroblast Growth Factor signaling pathwayDevelopment of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancerNovel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21.Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines.Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis.Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4.Modulation of Regorafenib effects on HCC cell lines by epidermal growth factorSustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex.The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells.FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation.Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patientsTrichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivoFibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibitionA call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma.Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.Fibroblast growth factor signaling in liver carcinogenesis.Approaches targeting the FGF-FGFR system: a review of the recent patent literature and associated advanced therapeutic agents.Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target.Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast.Novel therapeutic targets and predictive markers for hepatocellular carcinoma.Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.
P2860
Q26745338-6C6ADC6B-5CD5-4680-BBC3-9684ED5D1A95Q26752330-6D91F7D2-9C18-4456-85CC-46603CAC25FFQ26824909-95D9F785-2F90-46B5-98D0-DB2D91AB3B4EQ27686803-CD57FD0D-055D-432D-90D9-3D90978C456BQ28272678-5AAEAF5D-36CC-4644-9F1F-619F295C1BDAQ28484499-FA7F509B-55EF-4B3D-8588-46DBC0A94E4DQ30234616-0E5BC389-609B-4B8B-A369-770DD690EDADQ33405280-FB062C0D-7474-48A8-BC3D-73525545649DQ33412956-AE6F4BD9-4A3E-49DA-8E8F-00B912670D50Q33416414-F299B23F-9415-45D9-9CF6-D340E3B53A13Q33716459-9364249E-A14E-4C0A-81A4-F669A29A94DBQ33751398-1711C89A-AB8D-49B8-B0A1-EBFE7082F7ABQ33802709-A0F37940-7219-4FD3-9F36-4B38D83B7F49Q34330744-763CAF20-20ED-460C-ABC2-ECCFB95D1C79Q34467171-9F4CEBF0-392E-4517-A2F7-E03F59F8B3EEQ34525925-FBF0967E-77B8-43BE-BF1D-88E41CF4C4E1Q34733972-15C9B157-E739-45B8-BA40-78F9C30FFE7DQ34775779-35137160-00D9-4A4F-87F8-79599356117DQ34778879-A5010AE0-8554-4E0C-B0BF-D83EA51B302DQ34996693-60B03237-F67B-409C-9B68-2431A4CA4FF2Q35195305-4D729910-9FAC-495E-87A5-531465C01AF7Q35556797-E87B1FE2-34A6-4B03-B118-721F9849D2E0Q35639692-C516C610-DB44-4253-AC36-7769B6DDC0D9Q35947503-500CD95C-1E9C-4921-8B04-15DE6969B598Q36784812-52B9619C-EA59-48E5-9E9E-1EFE9FCEE318Q37046398-C64583A9-C6CC-4B95-A383-538C92EB0086Q37109765-C65F0ACB-D5EC-470F-B51F-2F093D91FBE8Q37295668-85DA4865-A473-44B8-8E70-B1F62E5C6037Q37620612-B4348F4D-4469-4A95-B195-AA9D24668512Q37631288-74F33FFC-0B46-4A53-A2E0-9831AEA4C082Q38083828-654E2993-B81C-42ED-92E9-952B1DEEFADBQ38160838-971AFF2B-CD8D-499A-AA70-4B5C3C765AC6Q38176101-A4FFFE48-27D7-4907-AD66-C9B88AEF7FC2Q38203285-DD6B9D63-14B0-42AD-99B5-BF0B2613E9ACQ38285703-A2E8F71C-F553-4B82-AE44-9232DDA0BEF0Q38303270-57FE6524-2503-4587-8B3B-A01E81E85177Q38354294-8D26DA7F-A0F7-41A4-8982-DB91CA8F3FAFQ38394171-EB9B09A1-AD2A-4F99-AF4B-B9A29B55E680Q38440838-EC19AD36-5A58-4CB8-A9B0-9575A8B48F1AQ38633258-AE5F1EA7-BC68-4704-B1FC-14414DE63726
P2860
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models
@ast
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models
@en
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models
@nl
type
label
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models
@ast
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models
@en
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models
@nl
prefLabel
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models
@ast
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models
@en
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models
@nl
P2093
P2860
P3181
P1433
P1476
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models
@en
P2093
Avi Ashkenazi
Benjamin C Lin
Brad Bolon
Camellia Adams
Craig Blackmore
Dorothy M French
Kathy Hötzel
Kurt Schroeder
Luc R Desnoyers
Luis A Rodriguez
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0036713
P407
P577
2012-01-01T00:00:00Z